Related references
Note: Only part of the references are listed.Lifelong Outcomes of Systemic Adeno-Associated Virus Micro-Dystrophin Gene Therapy in a Murine Duchenne Muscular Dystrophy Model
Nalinda B. Wasala et al.
HUMAN GENE THERAPY (2023)
Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update
Omar Sheikh et al.
ARCHIVES OF TOXICOLOGY (2022)
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
Merit E. Cudkowicz et al.
MUSCLE & NERVE (2022)
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
Laurent Servais et al.
NUCLEIC ACID THERAPEUTICS (2022)
Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence
Arianna Manini et al.
FRONTIERS IN NEUROLOGY (2022)
Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Feryal Alhamadani et al.
DRUG METABOLISM AND DISPOSITION (2022)
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Paula R. Clemens et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2022)
Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration
Hyunkee Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2022)
A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
Valeria Botti et al.
FRONTIERS IN PHARMACOLOGY (2022)
Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy
Joel Iff et al.
MUSCLE & NERVE (2022)
Drug development progress in duchenne muscular dystrophy
Jiexin Deng et al.
FRONTIERS IN PHARMACOLOGY (2022)
The new challenge of exercise plus X therapy for Duchenne muscular dystrophy -Individualized identification of exercise tolerance and precise implementation of exercise intervention
Yuhui Su et al.
FRONTIERS IN PHYSIOLOGY (2022)
Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
Gokce Eser et al.
GENES (2022)
Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study
Brenda L. Wong et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Maria Siemionow et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2022)
Emerging therapies for Duchenne muscular dystrophy
Theodora Markati et al.
LANCET NEUROLOGY (2022)
Duchenne Muscular Dystrophy Gene therapy
Fawzy A. Saad et al.
CURRENT GENE THERAPY (2022)
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Yang Du et al.
MOLECULAR BIOMEDICINE (2022)
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Maria Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2022)
Long term treatment with ataluren-the Swedish experience
Eva Michael et al.
BMC MUSCULOSKELETAL DISORDERS (2021)
Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model
Maria Siemionow et al.
STEM CELLS AND DEVELOPMENT (2021)
Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
Rebecca J. Willcocks et al.
JAMA NETWORK OPEN (2021)
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Ilaria Andreana et al.
PHARMACEUTICS (2021)
Mediterranean Diet, Brain and Nuscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Carla Petrella et al.
CURRENT MEDICINAL CHEMISTRY (2021)
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
Craig M. McDonald et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)
Metformin Increases Sarcolemma Integrity and Ameliorates Neuromuscular Deficits in a Murine Model of Duchenne Muscular Dystrophy
Xia Dong et al.
FRONTIERS IN PHYSIOLOGY (2021)
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial
Kathryn R. Wagner et al.
MUSCLE & NERVE (2021)
Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy
Reuven Tsabari et al.
NEUROMUSCULAR DISORDERS (2021)
Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy
Maria Siemionow et al.
STEM CELLS TRANSLATIONAL MEDICINE (2021)
Casimersen for Duchenne muscular dystrophy
H. Wilton-Clark et al.
DRUGS OF TODAY (2021)
Stem cell-based therapies for Duchenne muscular dystrophy
Congshan Sun et al.
EXPERIMENTAL NEUROLOGY (2020)
Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy
Hugh J. McMillan et al.
NEUROLOGY (2020)
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Diane E. Frank et al.
NEUROLOGY (2020)
Natural products, PGC-1α, and Duchenne muscular dystrophy
Ipek Suntar et al.
ACTA PHARMACEUTICA SINICA B (2020)
Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope
Tingting Jiang et al.
NATURE COMMUNICATIONS (2020)
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy A Nonrandomized Controlled Trial
Jerry R. Mendell et al.
JAMA NEUROLOGY (2020)
Stem cell therapy for muscular dystrophies
Stefano Biressi et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
Edward C. Smith et al.
PLOS MEDICINE (2020)
Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation
Jukka Partanen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial
Michael Taylor et al.
NEUROLOGY (2019)
CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
Yi-Li Min et al.
SCIENCE ADVANCES (2019)
What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?
Dominic J. Wells
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY (2019)
Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy
Libero Vitiello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption
Manoe J. Janssen et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Maria Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2019)
Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy
Michelle S. Parvatiyar et al.
JCI INSIGHT (2019)
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet
Francesco Muntoni et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy
Min J. Kim et al.
PHYSIOLOGICAL REPORTS (2019)
Effect of Combination L-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy A Randomized Clinical Trial
Patricia Hafner et al.
JAMA NETWORK OPEN (2019)
Aminoglycoside-mediated promotion of translation readthrough occurs through a non-stochastic mechanism that competes with translation termination
H. M. Chowdhury et al.
HUMAN MOLECULAR GENETICS (2018)
Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
Elinam Gayi et al.
CHIMIA (2018)
Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy
Seuk-Min Ryu et al.
NATURE BIOTECHNOLOGY (2018)
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans et al.
NEUROMUSCULAR DISORDERS (2018)
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
M. Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2018)
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Maria Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2018)
New Hope for Treatment of Duchene Dystrophy by Employing Dystrophin Expressing Chimeric Cells - Studies Published in Stem Cell Reviews and Reports
Mariusz Z. Ratajczak
STEM CELL REVIEWS AND REPORTS (2018)
Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies
Ahlke Heydemann
NUTRIENTS (2018)
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
M. Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2018)
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Maria Siemionow et al.
STEM CELL REVIEWS AND REPORTS (2018)
New Hope for Treatment of Duchene Dystrophy by Employing Dystrophin Expressing Chimeric Cells - Studies Published in Stem Cell Reviews and Reports
Mariusz Z. Ratajczak
STEM CELL REVIEWS AND REPORTS (2018)
Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism
Rasha Al-Khalidi et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Leonela Amoasii et al.
SCIENCE (2018)
Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment
Jessica Gonzalez-Sanchez et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2018)
The essential genome of the crenarchaeal model Sulfolobus islandicus
Changyi Zhang et al.
NATURE COMMUNICATIONS (2018)
Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy
Mattia Quattrocelli et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald et al.
LANCET (2017)
Progress toward Gene Therapy for Duchenne Muscular Dystrophy
Joel R. Chamberlain et al.
MOLECULAR THERAPY (2017)
SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy
Apurva Sarathy et al.
MOLECULAR THERAPY (2017)
Immunomodulatory Effects of Different Cellular Therapies of Bone Marrow Origin on Chimerism Induction and Maintenance Across MHC Barriers in a Face Allotransplantation Model
Mikael Hivelin et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2016)
Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study
Patricia Hafner et al.
PLOS ONE (2016)
Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice
Kristin N. Heller et al.
HUMAN GENE THERAPY (2015)
METFORMIN INCREASES PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ CO-ACTIVATOR-1α AND UTROPHIN A EXPRESSION IN DYSTROPHIC SKELETAL MUSCLE
Vladimir Ljubicic et al.
MUSCLE & NERVE (2015)
A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy
Nicholas P. Whitehead et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Increased AMP-activated protein kinase in skeletal muscles of Murphy Roth Large mice and its potential role in altered metabolism
Tirsit K. Berhanu et al.
PHYSIOLOGICAL REPORTS (2014)
The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy
Olivier M. Dorchies et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of dystrophin-associated protein complex components and satellite cell signaling
Katrin Hollinger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2013)
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2013)
Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening
Catherine Moorwood et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
AMPK Activation Stimulates Autophagy and Ameliorates Muscular Dystrophy in the mdx Mouse Diaphragm
Marion Pauly et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Dawn E. Bowles et al.
MOLECULAR THERAPY (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
Brief Report: Dystrophin Immunity in Duchenne's Muscular Dystrophy.
Jerry R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Jens Boch et al.
SCIENCE (2009)
Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants
M. Siemionow et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
PGC-1 coactivators and skeletal muscle adaptations in health and disease
Zolt Arany
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Muscle engraftment of myogenic progenitor cells following intraarterial transplantation
Estanislao Bachrach et al.
MUSCLE & NERVE (2006)
Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells
Daniel Skuk et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
P Miura et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Myogenic potential of muscle side and main population cells after intravenous injection into sub-lethally irradiated mdx mice
KR Muskiewicz et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2005)
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
FD Urnov et al.
NATURE (2005)
Development and maintenance of donor-specific chimerism in semi-allogenic and fully major histocompatibility complex mismatched facial allograft transplants
M Siemionow et al.
TRANSPLANTATION (2005)
Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores viability in dystrophic mice
DJ Burkin et al.
JOURNAL OF CELL BIOLOGY (2001)
Share Paper
